Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients

NCT02251067 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

165

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Nephropathy

Interventions

DRUG: VPI-2690B low dose
DRUG: VPI-2690B medium dose
DRUG: Placebo to match VPI-2690B
DRUG: VPI-2690B high dose

Sponsor

Vascular Pharmaceuticals, Inc.